Drug Profile
Research programme: gene targeting - Bristol-Myers Squibb/Lexicon Genetics
Latest Information Update: 01 Jun 2006
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; Lexicon Genetics
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Diabetes mellitus; Immunological disorders; Ischaemic heart disorders; Neurological disorders; Obesity; Psychotic disorders
Most Recent Events
- 01 Jun 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 01 Jun 2006 No development reported - Preclinical for Diabetes mellitus in USA (unspecified route)
- 01 Jun 2006 No development reported - Preclinical for Immunological disorders in USA (unspecified route)